Perspectives on Key MS Data From the Annual European MS Meeting
Integrating MRI Cortical Lesions in the Diagnosis of MS
Integrating MRI Cortical Lesions in the Diagnosis of MS (cont)
CARE MS I & II: MRI-Detected Lesions and NEDA
CARE-MS I and II: Rate of BVL
Spinal Cord Volume
Brain Atrophy as a Surrogate Marker for MS Progression
Perspectives on Key MS Data From the Annual European MS Meeting
Long-Term Effect of Therapy Effect of Year of MS Diagnosis on Reaching EDSS of 6
CARE-MS II: 5-Year Outcomes in Patients With HAD at Baseline
CARE-MS I and II: Autoimmunity With Alemtuzumab
CARE-MS I and II: Autoimmunity With Alemtuzumab (cont)
Use of Modified MSFC to Assess Efficacy of Daclizumab HYP and IFN-β1a IM on 24-Week Sustained Disability Progression
Use of Modified MSFC to Assess Efficacy of Daclizumab HYP and IFN-β1a IM on 24-Week Sustained Disability Progression (cont)
ENDORSE: Study Design
ENDORSE: Results
Perspectives on Key MS Data From the Annual European MS Meeting
NEDA: Definitions
Prognosis: ADVANCE and ATTAIN*
Prognosis: FREEDOMS and FREEDOMS II
Prognosis: FREEDOMS and FREEDOMS II (cont)
Achieving NEDA: DECIDE
Achieving NEDA: CLARITY and ONWARD
NEDA as Long-Term Therapeutic Goal: CARE-MS
NEDA: Practice Implications
NEDA: Practice Implications (cont)
NEDA: Practice Implications (cont)
Perspectives on Key MS Data From the Annual European MS Meeting
EXPAND: Siponimod in SPMS
RADIANCE Extension -- Ozanimod: Design
RADIANCE Extension -- Ozanimod: Results
ORATORIO: Subgroup Analysis
Autologous HSCT
ASCEND: Subgroup Analysis -- Design
ASCEND: Subgroup Analysis – Results
Abbreviations
Abbreviations (cont)
Abbreviations (cont)